Millennium Management’s Entera Bio ENTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-19,510
Closed -$32.6K 6043
2024
Q1
$32.6K Buy
19,510
+9,413
+93% +$10.4K ﹤0.01% 5756
2023
Q4
$6.06K Sell
10,097
-1,277
-11% -$871 ﹤0.01% 5800
2023
Q3
$8.25K Buy
+11,374
New +$8.38K ﹤0.01% 5794
2023
Q1
Sell
-46,000
Closed -$34K 6482
2022
Q4
$34K Buy
46,000
+35,968
+359% +$26K ﹤0.01% 5900
2022
Q3
$10K Sell
10,032
-6,833
-41% -$10.3K ﹤0.01% 6654
2022
Q2
$22K Sell
16,865
-29,344
-64% -$65.2K ﹤0.01% 6466
2022
Q1
$132K Buy
+46,209
New +$111K ﹤0.01% 6021
2021
Q4
Sell
-18,839
Closed -$89K 6938
2021
Q3
$89K Sell
18,839
-15,936
-46% -$81.7K ﹤0.01% 6474
2021
Q2
$208K Sell
34,775
-3,836
-10% -$14.2K ﹤0.01% 5990
2021
Q1
$147K Buy
+38,611
New +$88.9K ﹤0.01% 5597

Other funds holding ENTX

Millennium Management's ENTX Position: Q2 2024 in Review

Millennium Management sold out of Entera Bio (ENTX) in Q2 2024, closing a stake of 19,510 shares — an estimated $32.6K sold.

Millennium Management first reported a position in ENTX in Q1 2021 and held it in 10 quarters. The position peaked at $208K in Q2 2021. 15 funds tracked by Wall St. Rank hold ENTX as of Q2 2024.

  • Millennium Management reported no remaining Entera Bio position as of Q2 2024 after selling out during the quarter.
  • Millennium Management sold 19,510 Entera Bio shares in Q2 2024, an estimated $32.6K.
  • Millennium Management first reported a position in Entera Bio in Q1 2021 and held it in 10 quarters.
  • Millennium Management's Entera Bio position peaked at $208K in Q2 2021.
  • 15 funds tracked by Wall St. Rank held Entera Bio as of Q2 2024.

Based on Millennium Management's 13F filing for Q2 2024, filed 14 Aug 2024.